Narayanan said the company is confident of achieving $250 US sales in FY23.ĭon’t miss out on ET Prime stories! Get your daily dose of business updates on WhatsApp. Endo International said Tuesday it has entered into a settlement agreement with Florida under which the company will pay up to 65 million to resolve all government-related opioid claims in the state. The company plans to launch 4-5 products on a quarterly basis.Īnanthnarayanan said the acquisition business is expected to generate about $12 million - $14 million sales on a quarterly basis.Īnanthanaryanan said the fourth quarter could see a rollover of high cost raw materials and inventory. "We are also on track to launching products as we indicated from Q1FY23 onwards," Ananthnarayanan said. The Attorney General believes the complaint should be made available to the public in its entirety and efforts to keep it confidential will only prolong and diminish Endo’s accountability for its conduct."The green shoots are coming up, the business has started seeing growth, we have been able to retain market share and seeing new contracts being signed," Ananthanarayanan said.Īnanthanarayanan said the Chestnut Ridge facility which came with the acquisition of Endo portfolio has successfully completed a USFDA inspection with 2 minor observationsĪnanthnarayanan said the full sales benefit of the acquired portfolio will be seen from the fourth quarter. The order sealed by the judge allows the seal to expire in 10 days unless Endo acts to extend it. The Attorney General requested the complaint be filed under a temporary seal because Endo claims the information produced during the State’s investigation is confidential. Endo provided significant funding to other third-party groups and subsequently relied on material generated by those groups without disclosing the financial relationship. DUBLIN, Ap/CNW/ - Endo International plc (OTC: ENDPQ) announced today that its subsidiaries Endo Ventures Limited and Par Pharmaceutical, Inc. The State also has reason to believe Endo used the recommendations and educational materials of third-party groups like the American Pain Foundation without disclosing that Endo was by far the biggest donor to the Foundation and provided more than half of its total funding. 16 bankruptcy petition put a temporary pause on Pennsylvania’s coordinated opioid litigation, which lawyers have already criticized for. The Complaint alleges that Endo also knew the dangers of its opioid products, including increased risks of respiratory depression and death in elderly patients, and failed to clearly disclose those risks while it specifically targeted patients in that age group. Aleeza Furman Litigation Reporter Endo International’s Aug. It did this despite evidence to the contrary, including the FDA’s explicit rejection of Endo’s claim that Opana ER was resistant to abuse as well as overwhelming evidence that Opana ER was being abused throughout Tennessee. The allegations in the State’s 180-page complaint detail how Endo deceptively marketed its opioid products as being less addictive and more effective than others on the market. “Endo has repeatedly refused to take responsibility for its unconscionable conduct, which is why we are taking this action.” “Our Office has conducted an extensive investigation into Endo’s unlawful marketing practices which included targeting vulnerable populations like the elderly,” said Tennessee Attorney General Herbert H. The State’s lawsuit, filed in Knoxville, alleges Endo violated the Tennessee Consumer Protection Act and contributed to a devastating public health crisis in Tennessee. (Endo) for making unlawful and false claims about the safety and benefits of its opioid products. COPENHAGEN, Denmark, J(GLOBE NEWSWIRE) - Ascendis Pharma A/S (Nasdaq: ASND) today announced it will showcase its latest Endocrinology Rare Disease programs, data, and research in. Slatery III today sued Endo Pharmaceuticals and Endo Health Solutions Inc. Here are details from the news release by Attorney General Herbert Slatery’s office:Īttorney General Herbert H. The AG’s office says Endo violated the Tennessee Consumer Protection Act and contributed to a devastating health crisis in Tennessee. The Tennessee Attorney General is suing Endo for making unlawful and false claims about the safety and benefits of its opioid products. TN Attorney General sues opioid maker Endo Pharmaceuticals (photo courtesy Times News)Įndo Pharmaceuticals, the same company which was at the center of a $193 million settlement with one of James Hoyer’s whistleblower clients, is now facing another major legal battle.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |